Need an Angel? Find the Cancer Support You Need

Imerman Angels connects a person fighting cancer today ("cancer fighter") with someone who has beaten the same type of cancer ("cancer survivor"). The relationship provides a fighter the opportunity to ask personal questions and receive encouragement from someone who is uniquely familiar with the situation. The relationship provides a survivor the opportunity to personally help a fighter as he or she battles the disease.


The nature of the 1-on-1 relationship is up to each fighter-survivor pair. Perhaps the survivor will go to the fighter’s first chemotherapy treatment, or maybe the pair will simply speak on the phone from time to time. In other words, the fighter and survivor determine the depth of their own relationship.


In addition, Imerman Angels also connects “caregivers.” A caregiver is a friend or family member who is supporting a cancer fighter. Like fighters and survivors, they wish to be paired up with another caregiver who relates to and understands their situation. For instance, we have introduced the mother of a three-year-old cancer fighter to the mother of a four-year-old cancer survivor.


The service is absolutely free and helps anyone touched by any type of cancer, at any cancer stage level, at any age, living anywhere in the world.



If you’re a cancer fighter, survivor, or caregiver, please call toll-free at 1-877-274-5529 or email to info@imermanangels.org.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap